Clinical Trials Logo

Clinical Trial Summary

The main objective of this study is to determine the maximum tolerated dose (MTD) of OratecanTM. Eligible subjects of this study are patients with histologically or cytologically confirmed malignant solid tumor refractory to standard therapy or for which no established therapy exists at the time of study participation.


Clinical Trial Description

Besides the main objective, there are 3 other objectives as follows.

1. To determine dose-limiting toxicity (DLT) of OratecanTM

2. To characterize the pharmacokinetics of HM30181A, irinotecan and its metabolites (SN-38 and SN-38G) following oral administration of OratecanTM

3. To evaluate anticancer activity of OratecanTM in patients with advanced solid malignancies Groups of 3 patients per cohort or dose level will be treated with escalating doses of irinotecan in combination with a fixed 60mg dose of HM30181A.

If 0/3 patients at any dose level experience a DLT, the dose of irinotecan will be escalated by 10 mg/m2 in the next dose level. If 1/3 patients at any dose level experience a DLT, the cohort will be expanded by 3 additional patients to 6 patients. If no additional patients develop DLT, the dose of irinotecan will again be escalated in the next cohort of 3 patients. If 2/3 or 2/6 patients develop DLT, then dose escalation will cease, and the previous dose will be declared the MTD. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00979563
Study type Interventional
Source Hanmi Pharmaceutical Company Limited
Contact
Status Completed
Phase Phase 1
Start date July 2008
Completion date November 2010

See also
  Status Clinical Trial Phase
Terminated NCT02080078 - A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline Phase 1
Completed NCT00981721 - A Study to Determine the Pharmacokinetics of Cediranib in Chinese Patients With Advanced Solid Malignancies Phase 1
Terminated NCT00351325 - A Study of BMS-663513 Administered in Combination With Chemotherapy to Subjects With Advanced Solid Malignancies Phase 1
Completed NCT00295243 - Phase I Study of GW572016 With Topotecan to Treat Advanced Solid Malignancies Phase 1
Recruiting NCT02347228 - Evaluate Safety, Tolerability, PK, Preliminary Clinical Activity of OB318 in Patients With Advanced Solid Malignancies Phase 1
Terminated NCT00979134 - Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours Phase 1
Completed NCT00997945 - 10mg ZD4054 (Zibotentan) PK Study in Male, Elderly Chinese Patients With Advanced Solid Malignancies Phase 1
Completed NCT05573724 - Drug-drug Interaction Study With AZD5305 and Itraconazole in Patients With Advanced Solid Malignancies Phase 1
Completed NCT03736473 - A Phase I Study of MEDI9447 (Oleclumab) in Japanese Patients Phase 1
Completed NCT02260661 - Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours Phase 1
Terminated NCT01219543 - A Phase I Study of AZD1480 in Patients With Advanced Solid Malignancies and Advanced Hepatocellular Carcinoma in the Escalation Phase,Non-Small Cell Lung Cancer(NSCLC) and Non-smokers With Lung Metastasis and Gastric Cancer and Solid Tumour in the Expansion Phase. Phase 1
Completed NCT01213160 - Study to Assess Safety and Tolerability of AZD4547 in Japanese Patient Phase 1
Completed NCT00572364 - Open Label, Dose Escalation Phase I Study of AZD2281 Phase 1
Completed NCT03363893 - Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies Phase 1/Phase 2
Active, not recruiting NCT04606381 - A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies Phase 1
Recruiting NCT05315167 - A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Completed NCT00879905 - A Study of HSP990 Administered by Mouth in Adult Patients With Advanced Solid Tumors Phase 1
Terminated NCT00473616 - Phase I Single Ascending Dose/Multiple Ascending Dose in Patients Treated With AZD7762 and Irinotecan Phase 1
Recruiting NCT05159700 - A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors Phase 1
Completed NCT01813474 - Investigate the Safety and Tolerability of Olaparib Tablet in Japanese Patients With Advanced Solid Malignancies Phase 1